PCDHGB7 inhibits the progression of triple-negative breast cancer by suppressing XRCC5/MYC-mediated ribosome biogenesis

Ming Shan; Hongjie Bi; Hua Sun; Yixin Li; Zhiqi Li; Ziyuan Wang; Jianguo Dong; Shengbo Sang; Lili Ren; Yuguang Ye; Tianzhen Wang; Siniša Volarević; Rui Su; Lei Zhang; Minghui Zhang; Yan He; Guoqiang Zhang; Jing Li; Xiaobo Li

doi:10.1002/ctm2.70437

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (9) : e70437 DOI: 10.1002/ctm2.70437

LETTER TO THE JOURNAL

PCDHGB7 inhibits the progression of triple-negative breast cancer by suppressing XRCC5/MYC-mediated ribosome biogenesis

Author information +

¹. Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China

². Department of Pathology, School of Basic Medical Science, Harbin Medical University, Harbin, China

³. Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, California, USA

⁴. Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin, China

⁵. Department of Molecular Medicine and Biotechnology, University of Rijeka Faculty of Medicine, Rijeka, Croatia

⁶. Department of Oncology, Chifeng Municipal Hospital, Chifeng, China

⁷. Department of Radiotherapy, Harbin Medical University Cancer Hospital, Harbin, China

⁸. Center for Chronic Disease Prevention and Control, Harbin Medical University, Harbin, China

⁹. Key Laboratory of Preservation of Human Genetic Resources and Disease Control, Harbin Medical University, Ministry of Education, Harbin, China

cfzhangminghui@163.com

he_yan419@163.com

zhangguoqiang@hrbmu.edu.cn

lijing2020@hrbmu.edu.cn

lixiaobo@ems.hrbmu.edu.cn

Show less

History +

PDF

Cite this article

Download citation ▾

Ming Shan, Hongjie Bi, Hua Sun, Yixin Li, Zhiqi Li, Ziyuan Wang, Jianguo Dong, Shengbo Sang, Lili Ren, Yuguang Ye, Tianzhen Wang, Siniša Volarević, Rui Su, Lei Zhang, Minghui Zhang, Yan He, Guoqiang Zhang, Jing Li, Xiaobo Li. PCDHGB7 inhibits the progression of triple-negative breast cancer by suppressing XRCC5/MYC-mediated ribosome biogenesis. Clinical and Translational Medicine, 2025, 15(9): e70437 DOI:10.1002/ctm2.70437

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Barna M, Pusic A, Zollo O, et al. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature. 2008; 456(7224): 971-975.

[2]	Pelletier J, Thomas G, Volarevic S. Ribosome biogenesis in cancer: new players and therapeutic avenues. Nat Rev Cancer. 2018; 18(1): 51-63.

[3]	Tang J, Wang S, Weng M, et al. The IGF2BP3-COPS7B axis facilitates mRNA translation to drive colorectal cancer progression. Cancer Res. 2023; 83(21): 3593-3610.

[4]	Yan S, Frank D, Son J, et al. The potential of targeting ribosome biogenesis in high-grade serous ovarian cancer. Int J Mol Sci. 2017; 18(1): 210.

[5]	Ebright RY, Lee S, Wittner BS, et al. Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis. Science. 2020; 367(6485): 1468-1473.

[6]	Dai MS, Lu H. Crosstalk between c-Myc and ribosome in ribosomal biogenesis and cancer. J Cell Biochem. 2008; 105(3): 670-677.

[7]	Destefanis F, Manara V, Bellosta P. Myc as a regulator of ribosome biogenesis and cell competition: a link to cancer. Int J Mol Sci. 2020; 21(11): 4037.

[8]	Zhang Z, Zheng F, Yu Z, et al. XRCC5 cooperates with p300 to promote cyclooxygenase-2 expression and tumour growth in colon cancers. PLoS One. 2017; 12(10): e0186900.

[9]	Liu ZH, Wang N, Wang FQ, Dong Q, Ding J. High expression of XRCC5 is associated with metastasis through the Wnt signalling pathway and predicts poor prognosis in patients with hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2019; 23(18): 7835-7847.

[10]	Chen D, Chou FJ, Chen Y, et al. Targeting the radiation-induced ARv7-mediated circNHS/miR-512-5p/XRCC5 signalling with Quercetin increases prostate cancer radiosensitivity. J Exp Clin Cancer Res. 2022; 41(1): 235.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.